Tag - Tony Butler

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...